In this Registry study, manipulation of the CBUs
aimed at volume reduction was not shown to infl uence the clinical
outcome, indicating a satisfactory validation of the associated
technologies across the banks. Cells viability assessment methodology
varied among banks. Further eff orts to standardize the
quality controls before CBU release are needed